Today: 28 June 2026
Browse Category

NASDAQ:CMPS 4 November 2025 - 22 June 2026

Definium Therapeutics (DFTX) jumps in premarket on Phase 3 depression trial

Definium Therapeutics (DFTX) jumps in premarket on Phase 3 depression trial

Definium Therapeutics (DFTX) soared 64.2% pre-market to $40.19 after its Phase 3 Emerge trial showed DT120, an LSD-based tablet, achieved an 8.1-point placebo-adjusted benefit in major depressive disorder at week six, surpassing analyst expectations; investors now await results from a second trial and regulatory review, with approval and market access risks still ahead.
22 June 2026
··
Compass Pathways Rallies Pre-Market on FDA Trade Speculation

Compass Pathways Rallies Pre-Market on FDA Trade Speculation

Compass Pathways shares jumped 19.5% to $12.39 in U.S. premarket trading Monday after the company announced a faster FDA review path for its COMP360 psilocybin treatment. Management will address investors Tuesday at the RBC Capital Markets conference. Compass ended March with $466 million in cash and reported a first-quarter operating loss of $42.9 million.
18 May 2026
·
COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

COMPASS Pathways’ stock traded near $6 on Nov. 4, 2025, flat after a recent pullback and well above mid-year lows. The company reported a net loss of $137.7 million in Q3, with $185.9 million in cash on hand. Its lead psilocybin therapy met the primary endpoint in a Phase 3 trial for treatment-resistant depression in June. COMPASS is accelerating commercial plans and expects key data readouts in 2026.
4 November 2025
·

Stock Market Today

  • SpaceX Set to Join Nasdaq 100, Potential $4.3 Billion Market Boost for SPCX Stock
    June 28, 2026, 8:05 AM EDT. SpaceX ($SPCX), Elon Musk's aerospace and artificial intelligence firm, will join the Nasdaq 100 index on July 7. Inclusion in this key benchmark, which tracks the largest non-financial companies on the Nasdaq stock exchange, could trigger significant passive buying as index funds adjust holdings. Analysts estimate this shift may inject approximately $4.3 billion of demand into SPCX stock. This move underscores SpaceX's growing market footprint following its direct listing and highlights ongoing investor interest in the aerospace and technology sectors.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026
LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 8:08 AM EDT SpaceX Set to Join Nasdaq 100, Potential $4.3 Billion Market Boost for SPCX Stock June 28, 2026, 8:05 AM EDT. SpaceX ($SPCX), Elon Musk’s aerospace and artificial intelligence firm, will join the Nasdaq 100 index on July 7. Inclusion in this key benchmark, which tracks the largest non-financial companies on the Nasdaq stock exchange, could trigger significant passive buying as index funds adjust holdings. Analysts estimate this shift may inject approximately $4.3 billion of demand into SPCX stock. This move underscores SpaceX’s growing market footprint
Go toTop